|
WHAT:
|
Research study involving over 500 women locally (22,000 women nationally) to find out which of the two drugs being tested works better to prevent breast cancer with the least side effects.
|
|
WHY:
|
Breast cancer is one of the most common forms of cancer in women. Despite improvements in early detection, it remains one of our leading causes of cancer death. Scientists have learned enough about breast cancer to know that the use of a special kind of drug to block the female hormone "estrogen" from connecting to breast cells can reduce the development of cancer. This study will compare Tamoxifen with Raloxifene to test which works better in preventing breast cancer.
|
|
WHO:
|
Women at increased risk for developing breast cancer, who have gone through menopause and are at least 35 years old, can participate in the STAR trial. Menopause could have come naturally or by the result of a surgical procedure. All women must have an increased risk of breast cancer equivalent to or greater than that of an average 60-year-old woman. At that age, about 17 of every 1,000 women are expected to develop breast cancer within five years.
|
|
HOW:
|
Postmenopausal women who are interested in participating in STAR need to attend an educational session at the Tulane Cancer Center. The educational sessions will cover a variety of information ranging from eligibility criteria to financial issues. Please contact the Tulane Office of Clinical Research at 504-585-6121 to register for a session.
|
STAR announcement and information page
Other clinical trials at Tulane
Return to the top of this page.
Return to the Tulane Cancer Center homepage.